Results 131 to 140 of about 17,663 (255)

Implementation of OMOP and ConcePTION Common Data Models in CPRD GOLD: Risk of Bleeding and Cardiovascular Outcomes From Anticoagulant Use

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1574-1583, June 2026.
The impact of the choice of common data model (CDM) approach on the study results in a real‐world evidence (RWE) study is unknown. We aimed to determine potential differences in the results of an RWE study when data were mapped to two different CDMs, ConcePTION and OMOP. With the same instance of CPRD GOLD, data were mapped to both CDMs. Using the same
Nicholas B. Hunt, Patrick Souverein, Marloes Bazelier, Nicola Barclay, Antonella Delmestri, Miriam Sturkenboom, Daniel Prieto‐Alhambra, Helga Gardarsdottir, Olaf Klungel   +8 more
wiley   +1 more source

Ethnomedicinal Properties and Technological Challenges of Pomegranate Fruit as a Value‐Added Product

eFood, Volume 7, Issue 3, June 2026.
This review aims to provide a comprehensive review of pomegranate (Punica granatum) as a nourishing powerhouse, focusing on its remarkable nutritional conformation, bioactive composites, and substantial health assistance. This emphasizes the adaptableness and developing demand in the functional food market, as it discovers the potential solicitations ...
Muhammad Tayyab Arshad, Farhang Hameed Awlqadr, Sammra Maqsood, Hatem A. Al‐Aoh, Md. Sakhawot Hossain, Ali Ikram   +5 more
wiley   +1 more source

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, Volume 158, Issue 11, Page 2920-2927, 1 June 2026.
What's new? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

Therapeutics and Clinical Risk Management, 2018
Marco Proietti,1–3 Giuseppe Boriani4 1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy; 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK ...
Proietti M, Boriani G
doaj  

Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after atrial fibrillation‐related acute ischemic stroke.
Keon‐Joo Lee, Hoonji Oh, Han‐Gil Jeong, Beom Joon Kim, Moon‐Ku Han, Joon‐Tae Kim, Kang‐Ho Choi, Dong‐Ick Shin, Jae‐Kwan Cha, Dae‐Hyun Kim, Dong‐Eog Kim, Jong‐Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Mi‐Sun Oh, Kyung‐Ho Yu, Byung‐Chul Lee, Keun‐Sik Hong, Yong‐Jin Cho, Jay Chol Choi, Tai Hwan Park, Kyungbok Lee, Jee‐Hyun Kwon, Wook‐Joo Kim, Jun Lee, Ji Sung Lee, Da Young Hong, Juneyoung Lee, Philip B. Gorelick, Hee‐Joon Bae   +30 more
doaj   +1 more source

Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single‐Centre Tertiary Hospital

Australasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Apixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes.
Katherine J. Creeper, Grace Lenaghan, Aaron Stockwell, Matthew Schmidt, Katharine Ingram, Andrew C. Stafford   +5 more
wiley   +1 more source

Self-reported treatment burden: A comparison between vitamin K and non-vitamin K oral anticoagulants

Exploratory Research in Clinical and Social Pharmacy
Introduction: Treatment burden (TBN) refers to the impact of patients' healthcare-related workload on their functioning and well-being. A high TBN has been associated with lower adherence to treatment and increased risk of major adverse events, and ...
Miroslav Mihajlovic, Nevena Zec, Jelena Simic, Aleksandar Mihajlovic, Milan Marinkovic, Nebojsa Mujovic, Tatjana Potpara   +6 more
doaj   +1 more source

Non-Vitamin K Antagonist Oral Anticoagulants [PDF]

, 2016
Eduard Shantsila, Gregory YH Lip
openaire   +1 more source

Challenging Anticoagulation With Warfarin and Heparin Following Mechanical Mitral Valve Replacement in a Patient With Infective Endocarditis: A Case Report Highlighting Diagnostic Difficulties

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Warfarin remains the cornerstone of anticoagulation therapy following mechanical heart valve replacement. However, challenging anticoagulation responses, resistance to warfarin, and even more rarely to both warfarin and heparin pose significant clinical challenges and complicate management strategies.
Musawer Khan, Ayesha Ahmad, Moin Khan, F. N. U. Zainullah, Nauman Khan, Fatima Nazir, Wakil Ahmed, Naqeeb Ullah, Muhammad Anees, Kamil Ahmad Kamil   +9 more
wiley   +1 more source

Severe Multisystem Thrombotic Phenotype Associated With Protein C Deficiency in A Young Woman: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Severe protein C deficiency may present with recurrent multisystem thrombosis, including catastrophic mesenteric venous thrombosis in young adults. Early clinical suspicion, prompt imaging, and thrombophilia screening are essential for timely diagnosis and life‐saving intervention.
Akash Ahmed Alif, Mohammad Abul Kalam Azad, Tumpa Kundu, Masudul Hassan, Minhaj Rahim Choudhury, Shamim Ahmed   +5 more
wiley   +1 more source